Black Bird Biotech Provides Update As Global Concern Over Lasting Effects of Widely-Used Traditional Pesticides on Humans, Wildlife Continues to Rise

FLOWER MOUND, TX / ACCESSWIRE / July 19, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstream^TM biopesticide, confirmed that MiteXstream^TM is now registered in 47 states and D.C., with near-term clearance expected in Florida and Indiana. Initial registration in California is targeted for the first half of 2023. The company also confirmed that it recently began the process for obtaining registration in Peru, and that further international registration of MiteXstream^TM internationally, including in Canada and the EU, is scheduled to begin during the current quarter.

"It seems that every day there is a new report published that highlights the lingering toxicity of the pesticides that have been used all over the world, with these reports being accompanied with an urgent call to action for a better way to handle the pests. MiteXstream^TM answers that call, as a ‘pesticide re-imagined,' it is ‘gentle' enough to be completely non-toxic to bees, yet delivers high efficacy at low cost," said Fabian Deneault, BBBT's President. The reports on bees are available here and here.

According to Fortune Business Insights™, the Biopesticides Market is forecast to be worth $10.63 Billion for 2027, with a CAGR at 13.1%, which growth will be boosted by rising research activities to develop new microbial products.

A USDA report stated, "As the world's most important group of pollinators, bees are a crucial part of agricultural production and natural ecosystem function."

Black Bird Biotech is proud to offer the MiteXstream^TM product that is both an effective means of controlling pests, including spider mites, molds and other harmful agricultural issues while testing as not-toxic to honey bees.

MiteXstream^TM is currently available at MiteXstream.com and in the MiteXstream Amazon® Store.

For news and updates, shareholders, prospective investors and prospective business partners are encouraged to follow @BBBT_Corporate on Twitter and @BlackBirdBiotech on Instagram. Also visit BBBT's corporate website, BlackBirdBiotech.com, for additional information about the company.

About BBBT

Black Bird Biotech is positioned to exploit market segments with powerful, re-imagined biotech products. Its EPA-registered biopesticide, MiteXstream^TM, eradicates mites and similar pests, including spider mites (a lethal pest in cannabis, grapes, hops, coffee, strawberries and many other agricultural crops), and eliminates molds and mildews. MiteXstream^TM is a pesticide, but it is not a poison - it's a pesticide re-imagined. The MiteXstream^TM Edge: use through the day of harvest without concern for residual "pesticide" violations, including as it pertains to state cannabis testing. MiteXstream^TM is the foundational element of the company that carries vast potential worldwide as a highly effective, safe and extremely cost-effective replacement for many traditional "poisonous" pesticides.

Forward Looking Statements:

This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Eric Newlan
Vice President
833-223-4204
eric@newlanpllc.com
BlackBirdBiotech.com

SOURCE: Black Bird Biotech, Inc.